Download Master-Thesis
Total Page:16
File Type:pdf, Size:1020Kb
The impact of the revised EU-legislation concerning particular needs of blind and partially-sighted patients and user testing – a challenge for pharmaceutical companies with focus on Germany Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels „Master of Drug Regulatory Affairs“ der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von Dr. Ursula Schickel aus Limburg/Lahn Bonn 2007 Betreuer und 1. Referent: Frau Prof. Dr. B. Sickmüller Zweiter Referent: Herr W. Gering Table of Contents 1 Introduction............................................................................................................... 9 2 Braille requirements for labelling and the package leaflet ...................................... 10 2.1 Regulatory background....................................................................................... 10 2.2 The Braille alphabet............................................................................................ 11 2.3 Status of implementation at European member state level................................. 13 2.3.1 Status of implementation of Braille labelling in Germany............................. 13 2.3.1.1 Transition provisions................................................................................ 14 2.3.1.2 Facilitations according to German Drug Law............................................ 15 2.3.1.3 Marburg Medium for Braille characters .................................................... 16 2.4 Implementation of Braille on the packaging in the pharmaceutical industry........ 17 2.4.1 Preparation of Braille labelling on the packaging......................................... 17 2.4.1.1 Translation in Braille................................................................................. 17 2.4.1.2 Nationally different special characters in Braille for European languages 18 2.4.1.3 Braille labelling for multilingual packaging................................................ 20 2.4.1.4 Requirements for Braille on folding cartons (technical aspects)............... 21 2.4.2 Implications on the outer packaging materials, manufacture and release ...... procedures................................................................................................... 24 2.4.2.1 Description of necessary internal steps for creation of Braille labelling ....... on folding cartons and proposal for a workflow within pharmaceutical ........ companies ................................................................................................ 24 2.4.2.2 Implications for internal release of Braille-labelled folding cartons........... 28 2.4.2.3 Implications on regulatory activities for Braille labelling ........................... 29 2.5 Package information leaflets in formats appropriate for the blind and ................... partially-sighted................................................................................................... 30 2.5.1 Potential approaches for implementation in the pharmaceutical industry .... 31 2.5.1.1 Implementation in Germany: The RLS-Project......................................... 32 2.5.1.1.1 Technical aspects of the RLS-project ............................................... 34 2.5.1.1.2 Responsibilities according to the German Drug Law with respect ....... to the RLS-project and legal aspects ................................................ 35 2.5.1.1.3 Potential shortcomings of the RLS-project........................................ 37 2.5.1.2 Guidelines from the European Blind Union (EBU) and implementation ....... in the United Kingdom (UK), the Netherlands and Sweden...................... 38 2.6 Critical evaluation................................................................................................ 41 2.6.1 Braille labelling............................................................................................. 41 3 2.6.2 Package leaflets in formats appropriate for blind and partially-sighted ........... patients ........................................................................................................ 44 3 Readability of package leaflets of medicinal products for human use ................... 46 3.1 Regulatory and historical background................................................................. 46 3.1.1 Situation in Germany ................................................................................... 46 3.1.1.1 Purpose of package leaflets and liability aspects..................................... 47 3.1.2 Situation in Europe ...................................................................................... 47 3.1.3 Requirements for package leaflets and main objections.............................. 48 3.1.4 Readability guidelines on European level and in Germany.......................... 50 3.2 Consultation with target patient groups by interview technique based ................... on the “Australian method”.................................................................................. 53 3.2.1 Description and evaluation of procedure and major steps ........................... 54 3.2.1.1 Performing of and preparation for the test................................................ 55 3.2.1.2 Selecting participants and recruitment ..................................................... 57 3.2.1.3 Sample size and use................................................................................ 60 3.2.1.4 Success criteria........................................................................................ 61 3.2.1.5 Test protocol ............................................................................................ 63 3.2.2 Structure of testing report for marketing authorisation application............... 65 3.3 Description of further methods for testing ........................................................... 67 3.3.1 Standardised interview in writing according to Fuchs .................................. 67 3.3.2 Communication science based approach .................................................... 68 3.3.3 Communication and discussion with specific patient groups ....................... 70 3.4 Timing of submission to the competent authorities ............................................. 71 3.5 Justification for waivers and for bridging studies................................................. 75 3.5.1 Waivers........................................................................................................ 76 3.5.2 Bridging studies ........................................................................................... 79 3.6 Fields of general improvement concerning package leaflets and critical items ...... as per the draft “readability guideline”................................................................. 82 3.6.1 Structure of QRD-templates ........................................................................ 83 3.6.2 Extent and preciseness of package leaflets................................................. 84 3.6.3 Print size and design................................................................................... 85 3.6.4 Style............................................................................................................. 87 3.6.5 Syntax.......................................................................................................... 88 3.6.6 Print colour and symbols / pictograms ......................................................... 89 3.7 Outlook and critical evaluation ............................................................................ 91 4 Summary................................................................................................................ 97 5 References ............................................................................................................. 98 6 Appendices........................................................................................................... 108 4 Abbreviations AMG Arzneimittelgesetz (Medicinal Products Act; The German Drug Law) AOK Allgemeine Ortskrankenkasse (Statutory health insurance fund) AR Assessment Report BAH Bundesverband der Arzneimittel-Hersteller e.V. (German Medicines Manufacturers’ Association) BfArM Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices) BGG Behindertengleichstellungsgesetz (Equality law for disabled persons) BITV Barrierefreie Informationstechnik-Verordnung (Barrier-free communication technology regulation) Blista Deutsche Blindenstudienanstalt e.V. (German Study Institute for the Blind in Marburg) BPI Bundesverband der Pharmazeutischen Industrie e.V. (German Association of Pharmaceutical Industries) CBG MEB College Ter Beoordeling Van Geneesmiddelen - Medicine Evaluation Board (The Netherlands) CMD(h) Coordination Group for Mutual Recognition Procedures and Decentralised Procedures (human) CMS Concerned Member State CP Centralised Procedure CRO Contract Research Organisation CTD Common Technical Document DAISY Digital Accessible Information System DAZ Deutsche Apotheker Zeitung (German Journal for Pharmacists) DBSV Deutscher Blinden- und Sehbehindertenverband e.V. (The German Federation of Blind and Visually Impaired People) DCP Decentralised Procedure 5 DIN Deutsches Institut für Normung e.V. (German Standards Institute) DTD Document Type Definition DZB Deutsche Zentralbibliothek für Blinde (German Central Library for Blind) EAN International Article Number (former: Europan Article Number) EEC European Economic Community EBU